Novel Pharmacologic options in the treatment of neuropathic pain

CNS Spectrums

Volumn 9, Issue 10, 2004, Pages 1-16

  Irving, Gordon ^a,b   Goli, Veeraindar ^c,d   Dunteman, Edwin ^e,f  

^a Swedish Pain Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY   (United States)

^e A and A Pain Institute   (United States)

^f Pain Treatment Facility   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR STIMULATING AGENT; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BRADYKININ B1 RECEPTOR ANTAGONIST; CANNABINOID; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; GLYCINE RECEPTOR ANTAGONIST; IMMUNOMODULATING AGENT; KAPPA OPIATE RECEPTOR AGONIST; LIDOCAINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROKININ 1 RECEPTOR ANTAGONIST; NITRIC OXIDE; OPIATE; PAROXETINE; PREGABALIN; PROSAPOSIN; SAPORIN; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE;

ACUPUNCTURE; ALLODYNIA; BEHAVIOR THERAPY; CENTRAL NERVOUS SYSTEM; COGNITIVE THERAPY; DRUG TOLERANCE; HERBAL MEDICINE; HOMEOSTASIS; HUMAN; HYPNOSIS; MANIPULATIVE MEDICINE; MASSAGE; MEDITATION; NERVE EXCITABILITY; NERVE STIMULATION; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NERVOUS SYSTEM; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; RAT; REVIEW; SENSITIZATION;

EID: 8144230037     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (0)